Related references
Note: Only part of the references are listed.Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies
Dalibor Antolovic et al.
BMC BIOTECHNOLOGY (2010)
Increased EpCAM expression in malignant insulinoma: potential clinical implications
Andreas Raffel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma
Benoit Terris et al.
JOURNAL OF HEPATOLOGY (2010)
Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)
Karim El-Sahwi et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Identification of Polo-like Kinase 1 as a Potential Therapeutic Target in Anaplastic Thyroid Carcinoma
Tito Claudio Nappi et al.
CANCER RESEARCH (2009)
The Emerging Role of EpCAM in Cancer and Stem Cell Signaling
Markus Munz et al.
CANCER RESEARCH (2009)
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Robert C. Smallridge et al.
ENDOCRINE-RELATED CANCER (2009)
EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer
Du Wenqi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
iTRAQ-Multidimensional Liquid Chromatography and Tandem Mass Spectrometry-Based Identification of Potential Biomarkers of Oral Epithelial Dysplasia and Novel Networks between Inflammation and Premalignancy
Ranju Ralhan et al.
JOURNAL OF PROTEOME RESEARCH (2009)
Nuclear signalling by tumour-associated antigen EpCAM
Dorothea Maetzel et al.
NATURE CELL BIOLOGY (2009)
The detection of circulating tumor cells expressing E6/E7 HR-HPV oncogenes in peripheral blood in cervical cancer patients after radical hysterectomy
P. Weismann et al.
NEOPLASMA (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
A novel RET kinase-β-catenin signaling pathway contributes to tumorigenesis in thyroid carcinomal
Taranjit S. Gujral et al.
CANCER RESEARCH (2008)
EpCAM in morphogenesis
Monika Trzpis et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
EpCAM expression in normal, non-pathological tissues
Eva Schmelzer et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma
Giuliana Salvatore et al.
CANCER RESEARCH (2007)
Nuclear localization of beta-catenin involved in precancerous change in oral leukoplakia
Kosei Ishida et al.
MOLECULAR CANCER (2007)
Epithelial cell adhesion molecule - More than a carcinoma marker and adhesion molecule
Monika Trzpis et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges
M. A. Chaudry et al.
BRITISH JOURNAL OF CANCER (2007)
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
Catherine A. O'Brien et al.
NATURE (2007)
Identification and expansion of human colon-cancer-initiating cells
Lucia Ricci-Vitiani et al.
NATURE (2007)
Mutations and nuclear accumulation of β-catenin correlate with intestinal phenotypic expression in human gastric cancer
N. Ogasawara et al.
HISTOPATHOLOGY (2006)
EpCAM overexpression in thyroid carcinomas - A histopothological study of 121 cases
Christian Ensinger et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches
C Are et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Balancing cell adhesion and Wnt signaling, the key role of β-catenin
FH Brembeck et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2006)
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers
P Went et al.
BRITISH JOURNAL OF CANCER (2006)
Cyclin D1 overexpression in thyroid papillary microcarcinoma:: its association with tumour size and aberrant β-catenin expression
D Lantsov et al.
HISTOPATHOLOGY (2005)
Large-scale transcriptome analyses reveal new genetic marker candidates of head, neck, and thyroid cancer
EM Reis et al.
CANCER RESEARCH (2005)
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer
G Spizzo et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation
M Münz et al.
ONCOGENE (2004)
E-cadherin loss rather than β-catenin alterations is a common feature of poorly differentiated thyroid carcinomas
AS Rocha et al.
HISTOPATHOLOGY (2003)
Prospective identification of tumorigenic breast cancer cells
M Al-Hajj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
β-catenin signaling -: Therapeutic strategies in oncology
H Li et al.
CANCER BIOLOGY & THERAPY (2002)
Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue
J Stingl et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
β-Catenin dysregulation in thyroid neoplasms -: Down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis
G Garcia-Rostan et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus
YS Bian et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2000)
Share Paper
